A drug called semaglutide, known as Ozempic and Wegovy, has helped make Novo Nordisk the most valuable company in Europe. But starting Saturday, several countries will see the end of its patent protection. This means generic versions will soon be available in India, China, Canada, Brazil, Turkey, and South Africa. Together, these countries represent about 40% of the world’s population, bringing new hope for the millions with diabetes and obesity, as reported by the New York Times.
A treatment-access advocate from New Delhi put it simply: “These drugs, once only for the wealthy, will now be accessible to many more people.”
The excitement doesn’t stop there. In India, around 50 generic options are expected to hit the market soon. Analysts suggest this could create a $1 billion industry there. The BBC notes that increased competition could drop the price to around $15 a month. This would make it Easier for health services in middle-income countries to afford these medications, not just for diabetes but also for preventing serious conditions like heart attacks and strokes.
Novo Nordisk is feeling the pinch. Competing drugs from Eli Lilly and knock-off versions in the U.S. are posing challenges. The company has already reduced prices in some markets and is considering branding its original product as a premium offering to navigate this new landscape. However, for many in the U.S. and Europe, affordable generics might not arrive until the early 2030s due to patent extensions. Critics argue this delay could cost patients and taxpayers a staggering amount, potentially in the tens of billions.
Experts emphasize that the availability of generics will not only change the market dynamics but could also reshape public health policies. As accessibility increases, we might see a significant shift in how nations address obesity and diabetes, leading to healthier populations worldwide.
Source link
semaglutide,Novo Nordisk,India,China,Wegovy,Eli Lilly,obesity,diabetes,Ozempic
